MK-571
Based on 37 publication(s) in Google Scholar
MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.85%
- CAS No.: 115104-28-4
- Formule: C26H27ClN2O3S2
- Masse moléculaire:515.09
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-10010
Ko 143BCRP/ABCG2 Inhibitor -
HY-50879
ElacridarP-gp And BCRP Dual-Inhibitor -
HY-19989A
MK-571 sodiumABCC1/MRP4 Inhibitor -
HY-14275
VerapamilCalcium Channel Blocker -
HY-10583
Y-27632 dihydrochlorideROCK Inhibitor -
HY-10550
TariquidarP-gp Inhibitor -
HY-107608
Leukotriene B4PROTAC linker -
HY-17492
ZafirlukastLeukotriene Receptor Antagonist -
HY-15744
LY255283LTB4 Receptor Antagonist -
HY-15371
ForskolinAdenylate Cyclase Activator -
HY-15531
VenetoclaxBCL-2 Inhibitor -
HY-100558
Bafilomycin A1V-ATPase Inhibitor
Publications Citing Use of MedChemExpress (MCE) MK-571
More- Nature. 2026 May;653(8115):933-941. [Abstract]
- Cell. 2023 Dec 7;186(25):5500-5516.e21. [Abstract]
- Cancer Res. 2026 May 27:10.1158/0008-5472.CAN-25-5172. [Abstract]
- Nat Commun. 2023 Sep 19;14(1):5709. [Abstract]
- Adv Sci (Weinh). 2025 Aug 4:e04680. [Abstract]
- Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]
- Arch Toxicol. 2020 Nov;94(11):3799-3817. [Abstract]
- Cell Death Discov. 2024 Aug 14;10(1):364. [Abstract]
- Food Res Int. 2026 Mar 31:228:118352. [Abstract]
- Int J Nanomedicine. 2019 Nov 27:14:9217-9234. [Abstract]
- Free Radic Biol Med. 2024 Sep:222:229-243. [Abstract]
- Pharmaceutics. 2024 May 29;16(6):731. [Abstract]
- CNS Neurosci Ther. 2023 Jan;29(1):445-457. [Abstract]
- Commun Biol. 2024 May 23;7(1):621. [Abstract]
- Int J Mol Sci. 2026 Mar 13;27(6):2646. [Abstract]
- Chem Biol Interact. 2026 Aug 1:436:112206. [Abstract]
- Toxicology. 2025 Nov:517:154210. [Abstract]
- J Drug Deliv Sci Technol. 2025 May.
- Eur J Pharm Sci. 2023 May 1:184:106414. [Abstract]
- Brain Res Bull. 2022 Oct 15:189:69-79. [Abstract]
- Regul Toxicol Pharmacol. 2019 Nov:108:104449. [Abstract]
- Cancer Res Commun. 2024 Apr 9;4(4):1024-1040. [Abstract]
- Viruses. 2019 Apr 24;11(4):378. [Abstract]
- Drug Metab Dispos. 2026 Jun 29;54(8):100353.
- Drug Metab Dispos. 2025 Nov;53(11):100172. [Abstract]
- J Pharm Biomed Anal. 2020 Sep 10:189:113441. [Abstract]
- 3 Biotech. 2025 Apr;15(4):72. [Abstract]
- J Appl Toxicol. 2024 Nov;44(11):1725-1741. [Abstract]
- Toxicol Lett. 2020 Jul 1:327:9-18. [Abstract]
- Pharmacol Res Perspect. 2022 Feb;10(1):e00928. [Abstract]
- Eur J Drug Metab Pharmacokinet. 2024 Sep;49(5):609-617. [Abstract]
- Eur J Drug Metab Pharmacokinet. 2022 Mar;47(2):279-289. [Abstract]
- Cytotechnology. 2026 Jun;78(3):104. [Abstract]
- Xenobiotica. 2020 Mar;50(3):354-362. [Abstract]
- Eberhard Karls Universität Tübingen. 2022 Feb.
- Biomed Pharmacother. 2020 Sep:129:110506. [Abstract]
- Biomed Pharmacother. 2018 Oct:106:1563-1569. [Abstract]
Customer Validation & Images
-
IF
-
WB
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
Voir tous les produits spécifiques à Isoform Leukotriene Receptor
More
Activité biologique
Description
IC50 & Target
[1]|
LTD4 0.22 nM (Ki, In guinea pig lung) |
LTD4 2.1 nM (Ki, In human lung) |
LTD4 10.5 (pA2, on guinea pig ileum) |
LTE4 10.4 (pA2, on guinea pig ileum) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| GLC-4/ADR | IC50 |
0.4 μM
Compound: MK-571
|
TP_TRANSPORTER: inhibition of Daunorubicin uptake (Daunorubicin: 0.6 uM) in membrane vesicles from GLC4/ADR cells
TP_TRANSPORTER: inhibition of Daunorubicin uptake (Daunorubicin: 0.6 uM) in membrane vesicles from GLC4/ADR cells
|
[PMID: 10188979] |
| HEK293 | IC50 |
4 μM
Compound: MK-571
|
TP_TRANSPORTER: inhibition of PAH uptake (PAH: 0.1uM) in membrane vesicles from MRP2-expressing HEK cells
TP_TRANSPORTER: inhibition of PAH uptake (PAH: 0.1uM) in membrane vesicles from MRP2-expressing HEK cells
|
[PMID: 10760098] |
| HEK293 | IC50 |
10 μM
Compound: MK-571
|
TP_TRANSPORTER: inhibition of 9-(2-phosphonomethoxyethyl)adenine(PMEA) efflux (PMEA: 1 uM) in MRP4-expressing HEK293 cells
TP_TRANSPORTER: inhibition of 9-(2-phosphonomethoxyethyl)adenine(PMEA) efflux (PMEA: 1 uM) in MRP4-expressing HEK293 cells
|
[PMID: 12695538] |
| HEK293 | IC50 |
40 μM
Compound: MK-571
|
TP_TRANSPORTER: inhibition of 9-(2-phosphonomethoxyethyl)adenine(PMEA) efflux (PMEA: 1 uM) in MRP5-expressing HEK293 cells
TP_TRANSPORTER: inhibition of 9-(2-phosphonomethoxyethyl)adenine(PMEA) efflux (PMEA: 1 uM) in MRP5-expressing HEK293 cells
|
[PMID: 12695538] |
| HEK293 | IC50 |
2.9 μM
Compound: MK-571
|
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
|
[PMID: 22541068] |
| HEK293 | IC50 |
4.4 μM
Compound: MK-571
|
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
|
[PMID: 22541068] |
| HEK293 | IC50 |
6.4 μM
Compound: MK-571
|
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
|
[PMID: 22541068] |
| HEK293 | IC50 |
0.06 μM
Compound: MK571
|
Potentiation of etoposide-induced cytotoxicity against HEK293 cells assessed as etoposide IC50 at 25000 nM after 72 hrs by CCK8 assay (Rvb = 0.11 +/- 0.03 nM)
Potentiation of etoposide-induced cytotoxicity against HEK293 cells assessed as etoposide IC50 at 25000 nM after 72 hrs by CCK8 assay (Rvb = 0.11 +/- 0.03 nM)
|
[PMID: 27504669] |
| HEK293 | IC50 |
5.22 μM
Compound: MK571
|
Inhibition of human ABCC1 transfected in HEK293 cells assessed as potentiation of etoposide-induced cytotoxicity by measuring etoposide IC50 at 25000 nM after 72 hrs by CCK8 assay (Rvb = 38.54 +/- 5.62 nM)
Inhibition of human ABCC1 transfected in HEK293 cells assessed as potentiation of etoposide-induced cytotoxicity by measuring etoposide IC50 at 25000 nM after 72 hrs by CCK8 assay (Rvb = 38.54 +/- 5.62 nM)
|
[PMID: 27504669] |
| HEK293 | IC50 |
0.16 nM
Compound: MK-571
|
Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 25 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM)
Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 25 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM)
|
[PMID: 32347726] |
| HeLa | IC50 |
3.3 μM
Compound: MK-571
|
Inhibition of recombinant MRP1 expressed in human HeLa T5 cells assessed as ATP-dependent transport of [3H]para-aminohippurate
Inhibition of recombinant MRP1 expressed in human HeLa T5 cells assessed as ATP-dependent transport of [3H]para-aminohippurate
|
[PMID: 19580319] |
| HL-60 | IC50 |
0.5 μg/mL
Compound: MK-571
|
Ability to inhibit 50 nM Leukotriene C4 (LTC4) uptake into HL60/ADR membrane vesicles
Ability to inhibit 50 nM Leukotriene C4 (LTC4) uptake into HL60/ADR membrane vesicles
|
[PMID: 10612603] |
| L929 | IC50 |
>100 μM
Compound: MK571
|
Cytotoxicity against mouse L929 cells assessed as reduction in cell survival after 5 days by MTS assay
Cytotoxicity against mouse L929 cells assessed as reduction in cell survival after 5 days by MTS assay
|
[PMID: 30351934] |
| MDCK | IC50 |
>1000 nM
Compound: MK-571
|
Inhibition of ABCC2 overexpressed in MDCK cells at 100 uM by flow cytometric-based chloromethylfluorescein-diacetate accumulation assay
Inhibition of ABCC2 overexpressed in MDCK cells at 100 uM by flow cytometric-based chloromethylfluorescein-diacetate accumulation assay
|
[PMID: 19170519] |
| MDCK | EC50 |
2.85 μM
Compound: MK-571
|
Inhibition of MRP1 expressed in MDCK cells assessed as calcein AM accumulation by fluorescence assay
Inhibition of MRP1 expressed in MDCK cells assessed as calcein AM accumulation by fluorescence assay
|
[PMID: 20684594] |
| NCI-H69 | EC50 |
12.4 μM
Compound: MK-571
|
Modulation of MRP1 mediated drug efflux in doxorubicin-resistant human H69 cells assessed as accumulation of calcein AM incubated for 15 mins prior to calcein AM addition measured after 30 mins by fluorescence analysis
Modulation of MRP1 mediated drug efflux in doxorubicin-resistant human H69 cells assessed as accumulation of calcein AM incubated for 15 mins prior to calcein AM addition measured after 30 mins by fluorescence analysis
|
[PMID: 25311564] |
| Sf9 | IC50 |
2.62 μM
Compound: MK-571
|
TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.055 uM) in membrane vesicles from Mrp2-expressing Sf9 cells
TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.055 uM) in membrane vesicles from Mrp2-expressing Sf9 cells
|
[PMID: 11306690] |
| Sf9 | IC50 |
10 μM
Compound: MK-571
|
Inhibition of human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles
Inhibition of human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles
|
[PMID: 18457386] |
In Vitro
MK571 (15 μM, 1 h) markedly suppresses constitutive and Ag-stimulated S1P secretion from RBL-2H3 cells and mast cells, and inhibits Fluo-3 efflux[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RBL-2H3 cells, human LAD2 mast cells
-
Concentration:15 μM
-
Incubation Time:1 h
-
Result:Inhibited S1P secretion by vector and SphK1 transfected RBL-2H3 cells, whereas it did not affect uptake and intracellular conversion of [3H]Sph to S1P. Inhibited Fluo-3 efflux, inhibited S1P export by LAD2 cells, and blocked Ag-stimulated release of S1P.
In Vivo
MK-571 (0-1 mg/kg, orally, once) blocks LTD4- and Ascaris-induced bronchoconstriction in conscious squirrel monkeys[1].
MK-571 (0-25 mg/kg, orally, daily, for 2 more weeks) shows reversal of hypoxic pulmonary hypertension (PH), and protects mice from hypoxic PH[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hyperreactive rats (male and female, 200-400 g, pretreated intravenously with 3 μg/kg methysergide, 5 min before antigen chdlenge)[1]
-
Dosage:0.5, 0.15, and 0.05 mg/kg
-
Administration:Orally, once, 1 or 4 h before challenge
-
Result:Produced dose-dependent inhibition of the duration of antigen-induced dyspnea, with ED50 values of 0.13 (95% confidence interval (CI), 0.03-0.62) and 0.11 (95% CI, 0.009-1.47) mg/kg, respectively. MK-571 was even more active when administered orally as a suspension in 1% Methocel (4 h pretreatment), with an ED50 of 0.068 (95% CI, 0.83-0.14) mg/kg.
-
Animal Model:Csnscisus squirrel msnkeys[1]
-
Dosage:0.1, 0.5, and 1 mg/kg
-
Administration:Orally, once, 2 h prior to challenge with Ascaris antigen
-
Result:Produced significant inhibition of the bronchoconstriction at 0.5 mg/kg, produced significant inhibition of the increases in RL and decreases in Cdyn at 1 mg/kg.
-
Animal Model:FVB (Friend virus B-type) mice (Mrp4–/– and WT, 6 weeks old, exposed to chronic hypoxia (10% O2) in a ventilated chamber for 28 days)[2]
-
Dosage:0, 5, and 25 mg/kg
-
Administration:Orally, daily, for 2 more weeks, maintain in hypoxic conditions
-
Result:Showed reversal of hypoxic pulmonary hypertension (PH), and mice were protected from hypoxic PH. MK-571-treated mice displayed lower RVSP and Fulton index and a decrease in the medial thickening of small pulmonary arteries and arterioles.
Chemical Information
-
CAS No. 115104-28-4
-
Appearance Solid
-
Masse moléculaire 515.09
-
Formule C26H27ClN2O3S2
-
Color Off-white to light yellow
-
SMILES
O=C(O)CCSC(C1=CC=CC(/C=C/C2=NC3=CC(Cl)=CC=C3C=C2)=C1)SCCC(N(C)C)=O
-
Synonyms
L-660711
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (37)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 May;653(8115):933-941. PMID: 41851454 -
Cell
2023 Dec 7;186(25):5500-5516.e21. PMID: 38016470
MK-571 purchased from MedChemExpress. Usage Cited in: Cell. 2023 Dec 7;186(25):5500-5516.e21. [Abstract]
Survival curves for mice subjected to SD (SR means 48 h of recovery after SD) with oral administration of MK-571 sodium (0.1 mg/mL) (n = 10) in the drinking water compared with water controls (n = 10). The results showed that MK-571 sodium protected against SD-induced mortality.
-
Cancer Res
Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. [Abstract]2026 May 27:10.1158/0008-5472.CAN-25-5172. PMID: 42200804 -
Nat Commun
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. [Abstract]2023 Sep 19;14(1):5709. PMID: 37726279 -
Adv Sci (Weinh)
Fusidic Acid Reverses Chemoresistance in Breast Cancer via Targeting DDX6 to Downregulate GSK-3β/β-Catenin Signaling. [Abstract]2025 Aug 4:e04680. PMID: 40757496 -
Sci Adv
2024 Dec 13;10(50):eadq4274. PMID: 39661665
MK-571 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]
Cells were treated with the ABCC1 inhibitor MK-571 sodium (10 μM) and MRTX849 for 3 days, followed by CCK-8 assays. The results showed that MK-571 sodium improved the efficacy of MRTX849 in two resistant cells.
MK-571 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]
Cells were treated with 1 μM MRTX849 for 6 hours or with 10 μM MK-571 sodium for 24 hours, followed by 1 μM MRTX849 for 6 hours. Intracellular MRTX849 accumulation was quantified using LC-MS/MS (Student’s t test). The results showed that MK-571 sodium improved the efficacy of MRTX849 in two resistant cells.
-
Arch Toxicol
In vitro function and in situ localization of Multidrug Resistance-associated Protein (MRP)1 (ABCC1) suggest a protective role against methyl mercury-induced oxidative stress in the human placenta. [Abstract]2020 Nov;94(11):3799-3817. PMID: 32915249
MK-571 purchased from MedChemExpress. Usage Cited in: Arch Toxicol. 2020 Nov;94(11):3799-3817. [Abstract]
The MRP1 inhibitor MK-571 sodium (50 µM; 1 h) decreased A–B MeHg transport in MDCKII-MRP1 cells.
-
Cell Death Discov
Generation of a conditional cellular senescence model using proximal tubule cells and fibroblasts from human kidneys. [Abstract]2024 Aug 14;10(1):364. PMID: 39143064
MK-571 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Aug 14;10(1):364. [Abstract]
MK-571 (5 μM, 30 min) increased the fluorescence intensity of DOX-inducible CD10+ PTEC CMFDA metabolites.
-
Food Res Int
Hydroxypropyl-β-cyclodextrin as a co-delivery vehicle for synergistically enhancing fucoxanthin oral bioavailability through dual regulation of SR-B1 and ABCB1 transporters. [Abstract]2026 Mar 31:228:118352. PMID: 41703824 -
Int J Nanomedicine
The Optimization Design Of Lactoferrin Loaded HupA Nanoemulsion For Targeted Drug Transport Via Intranasal Route. [Abstract]2019 Nov 27:14:9217-9234. PMID: 31819426 -
Free Radic Biol Med
Mifepristone protects acetaminophen induced liver injury through NRF2/GSH/GST mediated ferroptosis suppression. [Abstract]2024 Sep:222:229-243. PMID: 38906233
MK-571 purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2024 Sep:222:229-243. [Abstract]
HT1080 cells were pretreated with Verapamil (20 μM) or MK-571 sodium (40 μM) for 2 h and then treated with DMSO or RU486 (5 μM) together with concentration gradient of RSL3 (0–10 μM) for 24 h. Cell viability was measured by CCK-8 (n = 3).
-
Pharmaceutics
Study on the Effect of Pharmaceutical Excipient PEG400 on the Pharmacokinetics of Baicalin in Cells Based on MRP2, MRP3, and BCRP Efflux Transporters. [Abstract]2024 May 29;16(6):731. PMID: 38931853 -
CNS Neurosci Ther
2023 Jan;29(1):445-457. PMID: 36253925 -
Commun Biol
2024 May 23;7(1):621. PMID: 38783088 -
Int J Mol Sci
LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells. [Abstract]2026 Mar 13;27(6):2646. PMID: 41898509 -
Chem Biol Interact
A microfluidic human blood-brain barrier model reveals neurovascular toxicity and barrier disruption induced by E-cigarette additives. [Abstract]2026 Aug 1:436:112206. PMID: 42285244 -
Toxicology
In vitro test battery for testing molecular initiating events in chemical-induced cholestasis. [Abstract]2025 Nov:517:154210. PMID: 40473197
MK-571 purchased from MedChemExpress. Usage Cited in: Toxicology. 2025 Nov:517:154210. [Abstract]
MK-571 (5 μM, 1 h) dilates the bile canalicular area in HepaRG cells.
MK-571 purchased from MedChemExpress. Usage Cited in: Toxicology. 2025 Nov:517:154210. [Abstract]
MK-571 (5 μM, 6 h) reduced the expression of NTCP, BSEP, and MRP3 in HepaRG cells.
-
-
Eur J Pharm Sci
Effect of budesonide on pulmonary activity of multidrug resistance-associated protein 1 assessed with PET imaging in rats. [Abstract]2023 May 1:184:106414. PMID: 36858275 -
Brain Res Bull
Ether lipid transfer across the blood-brain and placental barriers does not improve by inactivation of the most abundant ABC transporters. [Abstract]2022 Oct 15:189:69-79. PMID: 35981629 -
Regul Toxicol Pharmacol
2019 Nov:108:104449. PMID: 31449916 -
Cancer Res Commun
Inhibition of NEK2 Promotes Chemosensitivity and Reduces KSHV-positive Primary Effusion Lymphoma Burden. [Abstract]2024 Apr 9;4(4):1024-1040. PMID: 38592451 -
Viruses
Hepatitis C Virus-Induced FUT8 Causes 5-FU Drug Resistance in Human Hepatoma Huh7.5.1 Cells. [Abstract]2019 Apr 24;11(4):378. PMID: 31022917 -
-
Drug Metab Dispos
Activation of pregnane X receptor-organic anion transporting polypeptide 1a/b /P-glycoprotein/multidrug resistance protein 2 axis mediates the accelerated blood and liver clearance of PEGylated liposomes. [Abstract]2025 Nov;53(11):100172. PMID: 41106060 -
J Pharm Biomed Anal
Transport and metabolic profiling studies of amentoflavone in Caco-2 cells by UHPLC-ESI-MS/MS and UHPLC-ESI-Q-TOF-MS/MS. [Abstract]2020 Sep 10:189:113441. PMID: 32615340 -
3 Biotech
Triple regulation of oxidative-acetylation cycling pathways in COPD glucocorticoid resistance by HuaTanJiangQi capsules. [Abstract]2025 Apr;15(4):72. PMID: 40060290 -
J Appl Toxicol
Oleanolic acid induces hepatic injury by disrupting hepatocyte tight junction and dysregulation of farnesoid X receptor-mediated bile acid efflux transporters. [Abstract]2024 Nov;44(11):1725-1741. PMID: 39030772 -
Toxicol Lett
SOD2 promotes the expression of ABCC2 through lncRNA CLCA3p and improves the detoxification capability of liver cells. [Abstract]2020 Jul 1:327:9-18. PMID: 32201199 -
Pharmacol Res Perspect
The pharmaceutical excipient PEG400 affect the absorption of baicalein in Caco-2 monolayer model by interacting with UDP-glucuronosyltransferases and efflux transport proteins. [Abstract]2022 Feb;10(1):e00928. PMID: 35148019 -
Eur J Drug Metab Pharmacokinet
The ATP-Binding Cassette Transporter-Mediated Efflux Transport of Ganciclovir at the Blood-Brain Barrier. [Abstract]2024 Sep;49(5):609-617. PMID: 38963639 -
Eur J Drug Metab Pharmacokinet
Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood-Brain Barrier. [Abstract]2022 Mar;47(2):279-289. PMID: 35112329 -
Cytotechnology
Exploring the laxative effects of emodin on constipation through chloride channel activation. [Abstract]2026 Jun;78(3):104. PMID: 42083655 -
Xenobiotica
The potential role of human multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 2 (MRP2) in the transport of Huperzine A in vitro. [Abstract]2020 Mar;50(3):354-362. PMID: 31132291 -
-
Biomed Pharmacother
Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta. [Abstract]2020 Sep:129:110506. PMID: 32768979
MK-571 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Sep:129:110506. [Abstract]
MK-571 (50 μM, 10 min) increased the accumulation of [3H]-MVC in BeWo cells.
-
Biomed Pharmacother
Intestinal absorption mechanisms of araloside A in situ single-pass intestinal perfusion and in vitro Caco-2 cell model. [Abstract]2018 Oct:106:1563-1569. PMID: 30119231
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (194.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Jones TR, et al. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 1989 Jan;67(1):17-28. [Content Brief]
[2]. Hara Y, et al. Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest. 2011 Jul;121(7):2888-97. [Content Brief]
[3]. Mitra P, et al. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16394-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9414 mL | 9.7070 mL | 19.4141 mL | 48.5352 mL |
| 5 mM | 0.3883 mL | 1.9414 mL | 3.8828 mL | 9.7070 mL | |
| 10 mM | 0.1941 mL | 0.9707 mL | 1.9414 mL | 4.8535 mL | |
| 15 mM | 0.1294 mL | 0.6471 mL | 1.2943 mL | 3.2357 mL | |
| 20 mM | 0.0971 mL | 0.4854 mL | 0.9707 mL | 2.4268 mL | |
| 25 mM | 0.0777 mL | 0.3883 mL | 0.7766 mL | 1.9414 mL | |
| 30 mM | 0.0647 mL | 0.3236 mL | 0.6471 mL | 1.6178 mL | |
| 40 mM | 0.0485 mL | 0.2427 mL | 0.4854 mL | 1.2134 mL | |
| 50 mM | 0.0388 mL | 0.1941 mL | 0.3883 mL | 0.9707 mL | |
| 60 mM | 0.0324 mL | 0.1618 mL | 0.3236 mL | 0.8089 mL | |
| 80 mM | 0.0243 mL | 0.1213 mL | 0.2427 mL | 0.6067 mL | |
| 100 mM | 0.0194 mL | 0.0971 mL | 0.1941 mL | 0.4854 mL |
MK-571 Related Classifications
HY-19989 Related Classifications
Powered by Bioz